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ABSTRACT 
Melanin is produced through the process of melanogenesis, which serves to protect the skin from the damaging effects of UV radiation. Abnormal 
accumulation of melanin will aesthetically disturb even interfere with health. One of the clinical manifestations of abnormal accumulation of 
melanin is the incidence of melasma. Some of the tyrosinase enzyme inhibitor agents most widely used as Hydroquinone, Kojic acid and Arbutin do 
not give satisfactory results and cause serious side effects. Hydroquinone is known to cause ochronosis exogenous and cytotoxic. Kojic acid is 
known to cause allergies and mutagenic, while arbutinisis is known to have cytotoxic properties lower than hydroquinone, but less satisfactory 
depigmentation activity. There was a compound that has been synthesized by removing the hydroxy group of arbutin, known as deoxyarbutin (4-
[Tetrahydro-2H-Pyrans-2-yl) oxy] phenol). Deoxyarbutin (dA) shows Ki 10-fold is lower than hydroquinone and 350-fold is lower than arbutin. 
IC50dA is 17.5+0.5 µmol/l, while the IC50 hydroquinone is 73.7+9.1 µmol/l. In terms of security, dA indicates that cell viability is 95% higher than 
hydroquinone. However, dA is thermolabile and photolabile. Several studies have shown satisfactory results to improve the stability of dA, that 
these compounds are considerable potential for further development as a depigmentation agent. The aim of this review is to describe how the 
potency of dA as a tyrosinase inhibitor interferes melanogenesis process through the latest depigmentation agent, its safety, efficacy and stability. 
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INTRODUCTION 
Melanin is a biopolymer synthesized by the melanocyte cells in the 
cell organelles called melanosomes in epidermal layers of the skin 
[1-3]. Mature melanosomes are then transferred via intermediary 
dendrites into ceratine, resulting in the dark-colored coating on the 
corneum layer of skin epidermis [4-7]. Naturally, melanin serves as a 
photoprotective agent that protects DNA from damage due to UV 
radiation [8-10]. 
Melanin synthesized process is a combination of enzymatic catalysis 
and chemical reactions with tyrosinase [11-14] as the major enzyme. 
Moreover, tyrosinase can cause enzymatic browning in raw fruits, 
vegetables, and beverages. 
This enzyme plays a critical role in changing substrates in the form 
of L-tyrosine into L-dihydroxyphenylalanine (L-DOPA) via 
hydroxylation reaction, and the change of L-DOPA becomes 
dopaquinone through oxidation [15, 16]. This quinone compound is 
highly reactive and can polymerize spontaneously that at the end of 
the reaction it forms the melanin compounds. The formation of 
melanin is responsible for skin pigmentation condition that would 
interfere with the aesthetics of human [17-19]. Moreover, 
hyperpigmentation is caused by the accumulation of excess melanin 
production. It can cause quite serious skin problems, such as 
melasma, post-inflammatory melanoderma, solar lentigo, ochronosis 
exogenous, and dermatosis papu-losanigra [20-23]. Inhibition of the 
enzymatic activity of tyrosinase, both competitive and non-
competitive, is widely used as a key strategy in the development of 
depigmentation agent, either as cosmetics or the treatment of 
hyperpigmentation problems [24-27]. 
Some of the most used tyrosinase enzyme inhibitor agents are 
hydroquinone [11, 28, 29], kojic acid [30-33], and arbutin [34-38]. 
Hydroquinone is a tyrosinase inhibitor agent that has been used for 
a long time and become the gold standard in the treatment of 
hyperpigmentation in the USA [39, 40]. However, the use of 
hydroquinone in cosmetic preparations has been banned by FDA, 
and only allowed for the use of physician prescription. The FDA 
requested the use of hydroquinone is not exceeded more than 1.5–
2.0% in skin cosmetics product. This is due to the effect that 
hydroquinone can cause ochronosis exogenous and cytotoxic in the 
presence of reactive metabolites, such as, hydroxyl benzoquinone 
and p-benzoquinone [41-45].  
Natural product that contains stilbenes, uses tyrosinase inhibitors as 
skin whitening agents [46]. Sapindus mukorossi that grows in 
tropical and sub-tropical regions of Asia has weak bioactivity against 
tyronase with IC50 values of 17.8% and 12.3% at 10 μg/ml [47]. 
Curcumin-Mn and Zn has a potent as anti-tyrosinase capacity as a 
depigmentation agent [48] that can be studied further.  
In the previous study, Celastrus paniculatus seed oil exhibited 
superior tyrosinase inhibition activity than the standard ascorbic 
acid, kojic acid and arbutin [49]. Senol et al. found natural anti-
tyronase from the aerial parts of 33 Turkish Scutellaria species. 
However, the plant’s activity is moderate, ranged from 39.57% to 
51.58% inhibition [50]. The plants from common tropical plant 
species in the Indian subcontinent and Southeast Asia have been 
observed as a skin whitening treatment, and it has sub-nano molar 
activity. However, the IC50 is 60 times higher than kojic acid [51]. 
Tyrosinase inhibitory activity also is shown by the enzymatic 
hydrolysates of the collagen that obtained from the skin of squid 
(Todarodespacificus) [52]. 
Hydroquinone has very effective to inhibit melanogenesis thus can 
be used as a depigmentation agent. However, metabolite results 
from oxidation of hydroquinone by tryrosinase cause seriously 
adverse effects. DNA is damaged by hydroquinone as showed in 
studies against rodent models [53]. Furthermore, hydroquinone is 
banned in European Union, US FDA, and also in Indonesia for the 
cosmetic active ingredient.  
Some derivatives of hydroquinone has become much better than 
hydroquinone due to the decreasing its cytotoxycity, such us arbutin 
derivatives [54]. 
Kojic acid is an effective tyrosinase inhibitor agent both in vitro and in 
vivo [55-58]. However, these compounds have been banned in Japan for 
causing allergies and mutagenic [59]. Arbutin has been traditionally used 
by Japanese people to treat skin pigmentation disorders [60]. It is known 
to be an effective agent to address skin hyperpigmentation disorders. Its 
cytotoxic properties against melanocyte cells are lower than 
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hydroquinone, but depigmentation activity of arbutin is still far below 
hydroquinone depigmenting activity [61, 62]. 
In 2005, Boissy and his team synthesized a tyrosinase inhibitor 
agent and used arbutin as the parent compound, dA (4-[Tetrahydro-
2H-Pyrans-2-yl) oxy] phenol), by removing the hydroxy group on 
the compound of arbutin. This compound is proved to be more 
effective than other tyrosinase agent inhibitors and more secure [63, 
64]. There are known two form of arbutin, α-and β-arbutin. The both 
form of arbutin is hydroxylated by oxytyrosinase in ortho position of 
the catechol group thus to give rise to a complex formed by met-
tyrosinase with ydroxylated [37]. β-arbutin is naturally compound 
from Ericaceae and Saxi fragaceae [65]. On the other hand, α-arbutin 
is synthesized from hydorquinane using enzymatic or chemical 
reaction [66, 67]. In many study, α and β-arbutin has inhibit the 
formation melanin in B16 cell induced by α-melanocyte stimulating 
hormone (α-MSH) and inhibit tyronasinase activity [68]. Sugimoto et 
al. [62] explained that the α-arbutin has an effective and safe to use 
as skin lightening that decrease the cellular tyrosinase activity of 
HMV-II (Human Melanoma cell). The molecular mechanism of α-
arbutin against tyrosinase activity is studied by Gilibro et al. [69]. 
However, arbutin has some side effect to human skin in some cases. 
Arbutin cause allergic [70-72]. There are cases of allergic contact 
dermatitis caused by arbutin from Japan patients [71, 73].  
The other derivative of hydroquinone is deoxyarbutin (dA) that has 
more effective and safe clinically than arbutin to therapy 
hyperpigmentation. dA is second generation derivatives of 
hydroquinone [74]. dA is less cytotoxic than the others 
hydroquinone derivatives. This review summarized melanogenesis 
process and the role of tyrosinase inhibitor through the latest 
effective and safety compound, dA [75].  
The arrangement is automatically carried out by a substrate-induced 
melanogenic pathway (L-tyrosine and/or L-DOP). This arrangement 
will also regulate the function of melanocytes by structural or 
regulatory protein activity and through mediating melanogenesis 
and melanin itself [76].  
Melanogenesis 
Melanin is produced in the melanocytes cells through the process of 
melanogenesisin enzymatic or chemical reactions. Melanogenesis 
occurs in specialized organelles within melanocytes cells called 
melanosomes [77-80]. In normal circumstances, melanin serves to 
protect the skin from the damaging effects of UV radiation. The 
accumulation of abnormal melanin will cause aesthetic effects and 
disrupt health [75]. One of the clinical manifestations of abnormally 
accumulated melanin is the incidence of melasma, i.e. 
hyperpigmentation on the epidermis or dermis in the facial area that 
affects mainly the individual light-skinned, which included skin 
types III-IV, according to the classification of Fitzpatrick. It is more 
prevalent in women than associated with hormonal factors [81]. The 
auto regulate automatically itself is carried out by a substrate-
induced melanogenic pathway (L-tyrosine and/or L-DOP) and this 
arrangement will also regulate the function of melanocytes by 
structural or regulatory protein activity and through mediating 
melanogenesis and melanin itself [15]. 
The main targets are developed for depigmentation that inhibits the 
activity of tyrosinase enzyme, which is a precursor for the melanin 
synthesis [82]. Tyrosinase is a glycoprotein located on the membrane of 
melanosomes, and also dominated inside melanosomes, trans 
membrane, and in the cytoplasm of melanocyte cells. It is a monooxidase 
copper-dependent enzyme that has a role in catalyzing the conversion of 
monofenolic compound (L-tyrosine) into difenolic compound (L-DOPA) 
through hidroxilation process, and convert difenolic compound to 
quinone (benzoquinone) compound through an oxidation process [83]. 
The role of tyrosinase enzyme in melanin formation mechanism in the 
melanosomes within melanocytes cells and the processes that occur 
during melanogenesis itself [84]. 
The main substrate on melanogenesis enzymatic reaction is tyrosine. 
Tyrosine is hydroxylated by tyrosinase enzyme to be dopaquinone 
as a product of them. Dopaquinone will react with the cysteine-S to 
produce 5-cysteinyldopa and 2-S-cysteinyldopa in limited quantities. 
Cysteinyldopa is oxidized to produce benzothiazine followed by 
pheomelanin, a red pigment that causes blond hair. The absence of 
cysteine causes additional intramolecular amino groups for 
dopaquinone changed to be cyclodopa (Leucodopa-chrome). This 
compound then undergoes auto-oxidation and turned into dopa and 
dopachrome. Dopa is a substrate of tyrosinase enzyme too, therefore 
will oxidize back into dopaquinone. Next, dopachrome decomposes 
gradually and forms DHI and DHICA in very small amounts. The 
process is catalyzed by the tyrosinase-related enzyme protein-2 
(Tyrp2), which is now known as dopachrome tautomerase (Dct). 
Finally, hydroxyl indole compound is oxidized to eumelanin. 
Tyrosinase-related protein-1 (tyrp1) catalyzes the conversion of 
partially enzyme DHICA into eumelanin. Eumelanin is a blackish 
brown pigment that produces skin hyperpigmentation [85]. 
After the formation of melanin, melanin-shrouded melanosomes will 
be taken by melanocytes and transferred to the keratocytes cells, 
namely keratinocytes that have undergone differentiation. The 
transfer from melanocytes to keratinocytes is made through the 
tentacles of melanocyte (dendrites) approaching keratinocytes in 
the stratum above the basal layer. In the basal stratum 1, melanocyte 
cells are surrounded by 30-40 keratinocytes cells [86, 87]. 
Melanogenesis at a subcellular level 
In subcellular level, melanogenesisis encoded by the melanogenesis-
related enzyme, including tyrosine, Tryp 1 and Tyrp2 that are regulated 
through intracellular pathways. The signal of this pathway is initiated by 
some kinds of hormones including interleukin, growth factor, and 
prostaglandin. Some hormones also respond to a complex signal for their 
exposure to UV radiation or other stimulation that comes from the 
environment outside the body. Fig. 2 shows several signaling pathways 
that have been known to be actively involved in the process of 
melanogenesis at the subcellular level. All three of the signaling pathway 
involving microphthalmia-associated transcription factor (MITF), which 
is a transcription factor with the domain structure of basic helix-loop-
helix leucine zipper. In addition, its role in the proliferation and 
differentiation of melanocyte cell survival, MITF is also an important 
regulator that regulates the expression of genes for the formation of 
tyrosinase, Tyrp1, and Tyrp2. Up-regulation of MITF activity will activate 
the expression of the melanogenesis-related enzyme, which in turn will 
stimulate melanogenesis and vice versa, while down-regulation of MITF 
activity will suppress the expression of this enzyme that would inhibit 
melanogenesis [24, 88]. 
Alpha-melanocyte stimulating hormone (α-MSH) is a peptide 
derived from proopio melano cortine (POMC) [89], which regulates 
melanogenesis through cAMP pathway. α-MSH is released into the 
systemic circulation of the pituitary. It is related to 
melanocortin peptides, derived from the precursor POMC, which 
also expressed in numerous CNS and peripheral structures. 
When bound to its receptor namely melanocortine 1 receptor (MC1R) on 
melanocytes cell membrane, these hormones activate adenylyl cyclase 
(AC) to produce intracellular cAMP as the second messenger through the 
activation of G-protein-coupled receptors (GPCR). cAMP activates 
protein kinase A (PKA), which subsequently activate the MITF gene 
expression through phosphorilasic AMP response element-binding 
protein (CREB). Afterwards, MITF efficiently activates the 
melanogenesis-related enzyme and stimulates melanogenesis. Once α-
MSH is bound to the MC1R, the incidence of melanogenesis will increase 
by more than 100 times. Likewise with other POMC peptides are β-MSH 
and adrenocorticotropic hormone (ACTH), will stimulate melanogenesis 
via the same pathways [90]. 
Other signaling pathways that also activate MITF gene expression 
are the Wnt signaling pathway. The main key to this pathway is 
namely intracellular level of β-catenin. When the Wnt signal is 
absent, β-catenin is phosphorylated by glycogen synthase kinase-3β 
(GSK-3β). This phosphorylation recognized by the ubiquitin ligase 
complex, will degrade β-catenin [91]. Conversely, the signal Wnt-
activated would regulate GSK-3β, causing the accumulation of β-
catenin cytoplasmic translocates to the nucleus and forms a complex 
with the T-cell factor (TCF) and lymphocyte enhancer factor-1 (LEF), 
to download the up-regulation of gene expression MITF which in 
turn activates melanogenesis reaction via the same pathways [92]. 
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In the opposite of the aforementioned path, the path of an 
extracellular signal-regulated kinase (ERK) regulates melanogenesis 
through MITF protein degradation. ERK activates the 
phosphorylation of MITF through serine 73, followed by MITF 
ubiquination and proteasome-mediated degradation. As the result, 
the ERK pathway activation will inhibit melanogenesis, associated 
with down-regulation of MITF activity [34, 93].  
The internal and external factors of melanogenesis 
Melanocytes produce POMC peptides, cytokines, NO, prostaglandins, and 
leukotrienes that are activated through autocrine or paracrine pathway, 
associated with the production of adenylcyclase and cAMP as shown fig. 
1. Those receptors are within the immune response and inflammatory 
response, which are also involved in the process of pigmentation of the 
skin [20]. This creates some incidences of melanoderma post-
inflammatory, hyperpigmentation after an injury to the skin, and 
hyperpigmentation post-infection as in the case of chikungunya; as for 
other receptors in the melanocyte cells that are tied to the production of 
adenylcyclase and cAMP as muscarinic receptor and estrogen receptor α 
and β. Therefore, increased production of estrogen during pregnancy can 
cause hyperpigmentation such as melasma, hyperpigmentation areolar, 
and line nigricans [20]. 
 
 
Fig. 1: Melanogenesis at the subcellular level [34] 
 
Many extrinsic factors can trigger the occurrence of 
hyperpigmentation, such as the use of several kinds of drugs, 
chemicals, and even substances that are commonly used for the 
treatment of anti-aging and melisma, for example, hydroquinone 
which causes oncronosis exogenous—the formation of the blue to 
black pigment on skin tissue [34]. UV radiation is the main cause of 
skin hyperpigmentation. Rapid pigmentation can occur 5-10 min 
after exposure to UVR and disappear after a few minutes or days 
later. It usually occurs because of UVA radiation or delayed 
pigmentation in 3-4 d after exposure to UVR, and disappear after a 
few weeks due to UVA and UVB radiation [20]. 
UV radiation induces DNA damage which will be activated by p53 
(tumor protein suppressor). P53 stimulates the POMC gene 
undergone the post-translational, such asACTH, α-MSH, and β-
endorphin. The POMC peptide binds to MC1R on melanocytes, which 
further regulates melanogenesis through cAMP pathway [94]. 
Melanin is produced and transferred back to the keratinocytes. It has 
been mentioned that one POMC peptides bound to the MC1R, it lead 
a hundred times of melanogenesis incidence [34] that cause 
hyperpigmentation due to exposure of UV radiation.  
Deoxyarbutin synthesis 
dA compound (4-[Tetrahydro-2H-Pyrans-2-yl) oxy] phenol) 
designed by Boissy and his team for the first time in 2005, used 
quantitative structure-activity relationships (QSAR). This method is 
used as an approach to understanding the structural characteristics 
of the compounds. Although many techniques can be used in QSAR 
methods, but a basic understanding of this method is to convert the 
structure of a molecule or a part of the molecular structure to 
become a value numerically. In consequence, the value will be 
correlated with traits desired in an unknown compound [64]. 
The properties are optimized in this design. It is the competitive 
inhibition (at the binding site) of mushroom tyrosinase enzyme, 
inhibitor resistance to oxidation by the enzyme tyrosinase (thus can 
be an alternative substrate) and the molecule's ability to penetrate 
the skin. dA compounds are synthesized by eliminating the hydroxyl 
groups of the side chains of glucose group from arbutin as the parent 
compound as shown in fig. 2 [64]. The facile and highly efficient 
preparation of deoxyarbutin is recommended using a one-step 
catalyst-free continuous-flow etherification protocol. The one-step 
direct etherification obtains dA from hydroquinone through a 
continuous-flow, catalyst-free process [95]. 
 
 
Fig. 2: Conversion of arbutin compound into dA 
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The activity, efficacy and safety of deoxyarbutin 
dA is safer and less cytotoxic compared with hydroquinone [96]. Based 
on in vitro experiments against mushroom tyrosinase, it turns out that 
dA effectively inhibits mushroom tyrosinase with Ki 10 times lower 
than hydroquinone and 350 times lower than arbutin. The inhibition 
coefficient of dA, hydroquinone, kojic acid, and arbutinin μM is 0.05, 
0.54, 7.70, 17.60, respectively. In another study, dA is still stronger 
than hydroquinone that becomes the gold standard for melisma 
treatment. IC50 of dA(17.5+0.5 µmol/l) is lower than hydroquinone 
(73.7+9.1 µmol/l) when using mushroom tyrosinase assay and an 
inhibition coefficient of dA and hydroquinone at Ki 21.6+1.0 µmol/l 
and 83.1+5.9, respectively [97]. dA also could fight against tumour in 
vitro and in vivo. dA inhibits the proliferation and metastasis of tumour 
via a p38-mediated mitochondria [98]. 
Furthermore, dA in hairless guinea pigs shows skin lightening 
activity immediately and extended, where this activity is reversible 
after 8 w of discontinuation of topical application of dA. In contrast 
to the same study, hydroquinone skin-lightening activity has shorter 
onset but not extended, whereas kojic acid and arbutin show in 
significant skin lightening effect during the test [97]. Hydroquinone 
has some side effects with long-term application, such as melanocyte 
destruction, ochronosis and contact dermatitis [35]. 
In clinical trials conducted human subjects, topical application of dA 
in 12 w resulted in significant skin lightening on the subject who has 
light skin and improvements in solar lenities experienced in the 
dark-skinned population [64]. 
Other clinical trials conducted on the subject of 25 men and women 
ranged from 18-60 y old, for 5 w experiment, with the type of post-
exposure test (subjects were given prior to UV exposure for 7 d (tanning 
process) with a dosage test). The result showed that the percentages of 
the final tanning in control subjects (who were not given dosage), the 
subjects who had hydroquinone therapy and the subjects with dA 
treated are 44.6%, 51.6% and 37.3% respectively [63]. 
dA is a reversible inhibitor of the tyrosinase enzyme. It shows that 
the dA does not permanently damage the melanocytes. In further 
research by Hamed and his team in 2006, the study observed human 
melanocyte cell cultures. It showed that the maximum concentration 
of cell viability of dA is 95% higher than hydroquinone. It indicates 
that dA is not cytotoxic/cytostatic rather than HQ [63, 97]. 
Some of the previous toxicity tests show that dA is relatively safer 
than hydroquinone. Oral LD50 in rats as the subject to dA and 
hydroquinone is>2000 mg/kg and 298 mg/kg, respectively. The skin 
sensitization test proved that it has no potential to sensitize skin on 
dA treatment, while hydroquinone treatment shows potential to 
sensitize the skin. Dermal toxicity tests conducted with rats show 
that the dermal LD50 dA is more than 2000 mg/kg of body weight, 
while NOAEL values for hydroquinone is 74 mg/kg/day [99]. Nai-
Fang Chang et al. found that UVB-irradiated Arbutin and dA have 
strong cytotoxicity for the fibroblast cells [100]. Arbutin and dA is 
irradiated by UVB to form hydroquinone and end of product the 
toxic compound of 4-benzophenone [101]. dA has LD50 367 mg/kg 
in males and 314 mg/kg in females rats by serving for 4 d. 
The stability of deoxyarbutin 
In terms of stability, it is known that dA is thermolabile, especially in 
an aqueous solvent solution. When dA is stored for 14 d at a 
temperature of 45 °C, dA levels is plummeted to undetectable. At 25 
°C,dA level is decreased from 96.14% in the first day to 49.42% on 
21th day. At 4 °C, dA relatively shows a stable condition with 
concentration at 93.43% up to 21 d [102]. In the same study, dA 
degradation occurs in an aqueous solvent at high temperatures. 
Decreased dA levels per unit of time at high temperatures are 
directly proportional to an increase in hydroquinone levels [103]. 
In a solution with a solvent containing water within storage 
conditions at an elevated temperature, free electrons in the solvent 
can interact with oxygen atoms that lie between phenol group and 
tetrahydro-2H-pyrans on dA. Thus, it is degraded to hydroquinone 
and other molecules, such as tetrahydro-2H-pyrans-2-ol. The 
resulting hydroquinone (colorless) in aqueous solution will be 
oxidized to benzoquinone which changes the color of the solution to 
be brownish (fig. 3). 
 
 
Fig. 3: The dA degradation mechanisms in an aqueous solution becomes hydroquinone (colorless) and benzoquinone (brown) 
 
In an attempt to increase the stability of dA in preparations, some 
studies have observed dA stability in the system anhydrous 
emulsion formula with a base polyol-in silicone. The quantity of dA 
and the accumulation of hydroquinone as dA degradation products 
in aqueous solution are measured using HPLC [104]. The developed 
HPLC analytical method meets the validation criteria made by ICH. 
Muchtaridi et al. perform the analysis of dA using column C-18, UV 
detector 225 nm, methanol: water (60:40 v/v) as the mobile phase 
with isocratic elution; the flow rate is at 1 ml/min and the running 
time is 8 min. 
The research demonstrates that the anhydrous emulsion systems 
with a polyol-in silicone as a base (oil based), improve the stability 
dA in preparations and lead to delays degradation of deoxy-
arbutinin becoming hydroquinone at temperatures of 25 °C and 45 
°C [102]. 
As well as being thermolabile, arbutin and dA in aqueous solution 
are photolabile and create degradation products, such as 
hydroquinone. The concentration of hydroquinone increases during 
UV radiation in an aqueous solution containing arbutin and dA 
[101]. The release of the o-diphenol product forming deoxyarbutin is 
predicted be slower than in the case of β-arbutin using molecular 
modeling methods [105]. It contributes to its oxidation to a quinone 
before released from the protein into the water phase. 
In an effort to increase the stability of arbutin and dA against UVR 
exposure, Yang and his team (2013) in their study, added 
Benzophenone-4 in dA aqueous solutions and arbutin aqueous 
solutions. The treatment proved that it can increase the stability of 
the two substances against UV radiation exposure although not 
significant [101]. dA is insoluble in water, but it easily degrades in 
aqueous conditions. Tofani et al. (2016) formulates nanostructured 
lipid carriers (NLCs) to increased topical delivery of dA to inhibit 
tyrosinase during melanogenesis [106]. 
CONCLUSION  
The prospective of dA agent as a depigmentation agenthas a good 
efficacy, safety and stability. dA is tyrosinase inhibitor with good 
efficacy and relatively safe. It has higher potential as depigmentation 
agent than hydroquinone, which has been the gold standard of 
treatment of hyperpigmentation in the last decade. It has been 
demonstrated both in vitro and in vivo that the inhibition constants 
of dA and that IC50are lower than hydroquinone. In terms of security, 
dA is safer than hydroquinone, which has low potential to be 
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cytotoxic. In addition, based on other toxicity tests, dA is known to 
be more secure. However, dA is the rmolabile and photo labile. 
Several attempts have been made to improve the stability, such as 
making anhydrous emulsion formulations and adding sunscreen 
agents into the formula preparations. The development strategy and 
more advanced formulations of dA is required to improve the 
stability Therefore, not only preparations with dA have good 
potential and security but also good quality and stability during in 
storage, due to the effectiveness and safety of an active compound 
that cannot be achieved in unstable or degraded preparation in 
storage condition. 
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